Cargando…

Use of complementary and alternative medicine before and after organ removal due to urologic cancer

OBJECTIVE: Many patients use complementary and alternative medicine (CAM) as primary treatment or symptom relief for a variety of illnesses. This study was designed to investigate the influence of surgical removal of a tumor-bearing urogenital organ on CAM use. METHODS: From 2007 to 2011, 350 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mani, Jens, Juengel, Eva, Arslan, Ilhan, Bartsch, Georg, Filmann, Natalie, Ackermann, Hanns, Nelson, Karen, Haferkamp, Axel, Engl, Tobias, Blaheta, Roman A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599187/ https://www.ncbi.nlm.nih.gov/pubmed/26491269 http://dx.doi.org/10.2147/PPA.S90061

Ejemplares similares

I Publish in I Edit? - Do Editorial Board Members of Urologic Journals Preferentially Publish Their Own Scientific Work?
por: Mani, Jens, et al.
Publicado: (2013)

Publication of Original Research in Urologic Journals – A Neglected Orphan?
por: Mani, Jens, et al.
Publicado: (2012)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Detection of early DJ-stent encrustation by sonographic twinkling-artifacts – a pilot study
por: Blaheta, Roman A., et al.
Publicado: (2017)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
por: Tsaur, Igor, et al.
Publicado: (2015)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2016)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors
por: Jennewein, Lukas, et al.
Publicado: (2018)

Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)
por: Mani, Jens, et al.
Publicado: (2015)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
por: Juengel, Eva, et al.
Publicado: (2016)

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2016)

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2017)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Gender gap at a large European urological congress: still at the beginning
por: Hüsch, Tanja, et al.
Publicado: (2021)

Alternative or complementary attitudes toward alternative and complementary medicines
por: Berna, Fabrice, et al.
Publicado: (2019)

Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation
por: Juengel, Eva, et al.
Publicado: (2023)

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
por: Vallo, Stefan, et al.
Publicado: (2017)

Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro
por: Engl, Tobias, et al.
Publicado: (2018)

What should be the patient’s preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital
por: Mani, Jens, et al.
Publicado: (2016)

SARS-CoV-2 outbreak in medical employees in a large urologic department: Spread, containment and outcome
por: Brandt, Maximilian Peter, et al.
Publicado: (2021)

Utilization of surgical safety checklists by urological surgeons in Germany: a nationwide prospective survey
por: Borgmann, Hendrik, et al.
Publicado: (2015)

Complementary and alternative medicine use by pediatric oncology patients before, during, and after treatment
por: Lüthi, Emmanuelle, et al.
Publicado: (2021)

Alternative/complementary possibilities
por: Carli, C, et al.
Publicado: (2011)

Complementary and alternative medicine
por: Bellanger, Renee A., et al.
Publicado: (2021)

Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
por: Borgmann, Hendrik, et al.
Publicado: (2021)

The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results
por: Engel, Oliver, et al.
Publicado: (2014)

Complementary and Alternative Approaches to Biomedicine
por: Matsuba, Shintaro
Publicado: (2004)

The Perils of Complementary Alternative Medicine
por: Bayme, Michael J., et al.
Publicado: (2014)

Complementary and Alternative Medicine for Diabetes
por: Yang, Wen-Chin, et al.
Publicado: (2013)

The Complementary and Alternative Medicine for Antithrombosis
por: Yang, Feng-Qing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jil2bcm9icmf17fvinmih4m0se